OraSure Technologies, Inc. Corporate Fact Sheet
1 / 3ページ

OraSure Technologies, Inc. Corporate Fact Sheet Headquarters 220 East First Street Bethlehem, PA 18015 Telephone: 610-882-1820 Fax: 610-882-1825 Web site: Stock symbol: NASDAQ: OSUR Executive Officers • Douglas A. Michels, President and Chief Executive Officer • Ronald H. Spair, Chief Operating Officer and Chief Financial Officer • Anthony Zezzo, Executive Vice President Sales and Marketing • Jack E. Jerrett, Senior Vice President, General Counsel and Secretary • Mark L. Kuna, Senior Vice President, Finance and Controller Executive Team • Douglas A. Michels, President and Chief Executive Officer • Ronald H. Spair, Chief Operating Officer and Chief Financial Officer • P. Michael Formica, Executive Vice President and General Manager, Cryosurgery • Anthony Zezzo, Executive Vice President Sales and Marketing • Jack E. Jerrett, Senior Vice President, General Counsel and Secretary • Mark L. Kuna, Senior Vice President, Finance and Controller • Henry B. Cohen, Senior Vice President, Human Resources • Debra Y. Fraser-Howze, Senior Vice President, Government and External Affairs • Nancy McLane, Senior Vice President, Operations • Ron Ticho, Senior Vice President, Corporate Communications • Jill Thompson, Senior Vice President, Business Development • Kathleen Weber, Senior Vice President and General Manager, Consumer Products Company Overview OraSure Technologies is a leader in the development, manufacture and distribution of point of care diagnostic and collection devices and other technologies designed to detect or diagnose critical medical conditions. Its first- to-market, innovative products include rapid tests for the detection of antibodies to HIV and HCV on the OraQuick® platform, oral fluid sample collection, stabilization and preparation products for molecular diagnostic applications, and oral fluid laboratory tests for detecting various drugs of abuse. OraSure's portfolio of products is sold globally to various clinical laboratories, hospitals, clinics, communitybased organizations and other public health organizations, research and academic institutions, distributors, government agencies, physicians' offices, commercial and industrial entities and consumers. The Company's products enable healthcare providers to deliver critical information to patients, empowering them to make decisions to i

OraSure Technologies – Product Offering Infectious Disease ® • OraQuick ADVANCE Rapid HIV-1/2 Antibody Test – the first FDA approved, CLIA-waived, rapid point-ofcare test that can detect antibodies to both HIV-1 and HIV-2 with greater than 99% accuracy in as little as 20 minutes, using an oral fluid, finger-stick or venipuncture whole blood, or plasma sample. ® • OraQuick In-Home HIV Test – the first and only oral fluid rapid OTC HIV test approved in the U.S. The ® OraQuick In-Home HIV Test can detect antibodies to both HIV-1 and HIV-2 with an oral swab, providing a confidential in-home...

Selected Financial Information T w e l v e Months Ended December 31, 2015 (000’s) (Unaudited) 2015 Revenues Net Income (Loss) Earnings (Loss) per share – Basic a n d Diluted Number of shares -- Basic Diluted Investor Relations Contact Ronald H. Spair, CFO 610-882-1820 ext. 3279 investorinfo@orasure.com Media Contact Jennifer Moritz 917-748-4006 jmoritz@0to5.com